Coloplast A/S (ETR:CBHD)
Germany
· Delayed Price · Currency is EUR | Market Cap | 14.71B |
| Revenue (ttm) | 3.73B |
| Net Income (ttm) | 534.11M |
| Shares Out | n/a |
| EPS (ttm) | 2.37 |
| PE Ratio | 27.54 |
| Forward PE | 18.91 |
| Dividend | 3.08 (4.77%) |
| Ex-Dividend Date | Dec 5, 2025 |
| Volume | 767 |
| Average Volume | 1,395 |
| Open | 65.20 |
| Previous Close | 64.48 |
| Day's Range | 64.86 - 65.58 |
| 52-Week Range | 63.06 - 104.95 |
| Beta | 0.59 |
| RSI | 41.13 |
| Earnings Date | Feb 6, 2026 |
About Coloplast
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories ... [Read more]
Financial Performance
In fiscal year 2025, Coloplast's revenue was 27.87 billion, an increase of 3.12% compared to the previous year's 27.03 billion. Earnings were 3.64 billion, a decrease of -28.03%.
Financial numbers in DKK Financial StatementsNews
Coloplast A/S - Updated Financial Calendar 2025-26
Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General ...
Coloplast A/S (CLPBY) Q1 2026 Earnings Call Transcript
Coloplast A/S (CLPBY) Q1 2026 Earnings Call Transcript
Coloplast A/S - Interim Financial Report, Q1 2025/26
2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth1 in constant currencies of 3%. Reported revenue in DKK grew 0%...
Coloplast announces changes to Executive Leadership Team
Today, Coloplast is announcing changes to the company's Executive Leadership Team (ELT). The changes relate to the company's Interventional Urology business as well as the global People & Culture func...
Coloplast A/S (CLPBY) Shareholder/Analyst Call Transcript
Coloplast A/S (CLPBY) Shareholder/Analyst Call Transcript
Coloplast A/S - Decisions at the Annual General Meeting 2025
Today, 4 December 2025, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2024/25 was approved. Distribution of y...
Coloplast A/S - Notice of Annual General Meeting 2025
Notice of Annual General Meeting 2025 The Annual General Meeting of Coloplast A/S will be held on Thursday, 4 December 2025 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the...
Coloplast A/S (CLPBY) Q4 2025 Earnings Call Transcript
Coloplast A/S (OTCPK:CLPBY) Q4 2025 Earnings Call November 4, 2025 5:00 AM EST Company Participants Lars Rasmussen Anders Lonning-Skovgaard - Executive VP & CFO Conference Call Participants Hassan Al-...
Coloplast Finance B.V. - Annual Report, 2024/25
Hereby please find the Annual Report 2024/25 for the group of Coloplast A/S. Attachment 11_2025_Annual_Report_2024-25
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25 FY 2024/25 organic growth of 7% and EBIT margin1 of 28%. Reported revenue in DKK grew 3% to DKK 27,874 million.
After A 50% Decline, Coloplast Might Finally Be Worth Buying
Coloplast is now rated a cautious 'Buy,' as its valuation has become more reasonable after a significant price correction. Coloplast continues to deliver solid organic growth, boasts a wide economic m...
Coloplast A/S - FY 2024/25 Earnings Release - Invitation for conference call on 4 Nov 2025 at 11.00 CET
Tuesday, 4 November 2025 at 11:00 - 12:00am CET In connection with the publication of Coloplast's interim financial results for FY 2024/25, to be released same day around 07.00am CET, Coloplast will h...
Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting
Announcement no. 09/2025Inside information Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting Coloplast interim CEO Lars Rasmussen has today i...
Coloplast A/S - Financial Calendar 2025-26
Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://www.coloplast.com/investor-relations/events-calendar/ Kind regards,Investor RelationsC...
Coloplast A/S (CLPBY) Capital Markets Day 2025 Transcript
Coloplast A/S (OTCPK:CLPBY) Capital Markets Day 2025 September 2, 2025 4:30 AM EDT Company Participants Lars Rasmussen Anders Lonning-Skovgaard - Executive VP & CFO Caroline Rosenstand - Executive Vic...
Coloplast A/S - Coloplast presents new 5-year strategy, Impact4
The new 5-year strategy, Impact4, will be presented today at the company's Capital Markets Day 2025 The Impact4 strategy puts customers at the centre of everything we do and sets an ambitious goal for...
Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new financial ambition towards 2030
In relation to the launch of Coloplast's new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in li...
Coloplast A/S (CLPBF) Q3 2025 Earnings Call Transcript
Coloplast A/S (OTCPK:CLPBF) Q3 2025 Earnings Conference Call August 19, 2025 5:00 AM ET Company Participants Anders Lonning-Skovgaard - Executive VP & CFO Lars Soren Rasmussen - Interim CEO & Director...
Coloplast A/S - Interim Financial Report, 9M 2024/25
Coloplast A/S - Interim Financial Report, 9M 2024/25 2024/25 Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in ...
Coloplast A/S – Updated presenters list for Capital Markets Day on 2 September 2025
Following the changes to the Executive Leadership Team, announced on 19.08.2025*, we are pleased to share with you the updated presenters list for our Capital Markets Day on 2 September 2025. For thos...
Coloplast A/S - Announcement no. 05/2025 - Coloplast announces changes to Executive Leadership Team
Coloplast announces changes to Executive Leadership Team The Coloplast Board of Directors are making changes to the Executive Leadership Team (ELT) to support the successful execution of the new Colop...
Coloplast A/S - 9M 2024/25 Earnings Release - Invitation to conference call on 19 August 2025 at 11.00am CEST
Tuesday, 19 August 2025 at 11.00 - 12.00h CEST In connection with the publication of Coloplast's interim financial results for 9M 2024/25, to be released same day in the morning around 07.30h CEST, Co...
Coloplast: Finally Getting Buyable
Coloplast is a global leader in specialized intimate healthcare, with strong innovation, high margins, and a defensible moat in core segments. Despite a 20% share price drop, I see upside potential, b...
Coloplast A/S - Invitation to Coloplast's Capital Markets Day on 2 September 2025
The event will take place on Tuesday, 2 September 2025 at Clarion Hotel (Copenhagen airport) Ellehammersvej 20, 2770 Kastrup from 10.30 - 17.00 CEST (Central European Summer Time)
Coloplast A/S (CLPBF) Q2 2025 Earnings Call Transcript
Coloplast A/S (OTCPK:CLPBF) Q2 2025 Earnings Conference Call May 6, 2025 5:00 AM ET Company Participants Lars Søren Rasmussen - Interim CEO Anders Lonning-Skovgaard - Chief Financial Officer Conferenc...